Prof Manuel Salto Tellez

Prof Manuel Salto Tellez

QUB

Professor Manuel Salto-Tellez (MD-LMS, FRCPath, FRCPI) is the Chair of Molecular Pathology at Queen’s University Belfast, and the Lead of the Queen’s Precision medicine centre of Excellence.

By January 2019, Prof Salto-Tellez was author or co-author of more than 260 internationally peer-reviewed articles in translational science, molecular pathology and diagnostics. He has published a similar number of abstracts in international conferences, and is editor or contributor to some of the key textbooks of pathology and oncology.

He studied Medicine in Spain (Oviedo), Germany (Aachen) and The Netherlands (Leiden). He specialized in Histopathology in the UK (Edinburgh and London) and in Molecular Pathology in USA (Philadelphia). For more than 10 years he worked at the National University of Singapore and its National University Hospital, where he was associate professor, senior consultant, director of the Diagnostic Molecular Oncology Centre, Vice-dean for Research and senior scientist at the Cancer Research Institute.

Prof Salto-Tellez serves in committees associated with CRUK, NICE and REF, among others. He holds more than £15M in competitive grant funding, including the new Precision Medicine Centre of Excellence, a visionary development aiming to redefine the process of biomarker development and test adoption in the UK and globally.

Abstract
Histopathology became an established, global and accepted clinical discipline in the first half of the 20th Century. Since then 3 main developments have reshaped the way we practice it.

Immunohistochemistry (IHC) [1] provided important information in both diagnostic and discovery, helping the delivery of a more accurate and sophisticated taxonomy of diseases (diagnostic value), and also the performance of key tests with a genetic, prognostic and predictive value [2]. The second revolution (“the molecular diagnostic revolution”) was different and, in many occasions, this analysis has been performed outside the routine pathological strategies, making pathologists facilitators rather thean leaders in this field [3, 4].

In our opinion, Digital Pathology (DP) and Artificial Intelligence (AI) represents an incipient “third revolution” that is strongly knocking at the door of pathology. From a practical point of view, DP/AI have the potential to make the complex and fragmented pathway of routine pathological tissue interrogation a more seamless endeavour at, at least, 3 levels, namely a) the analysis of H&E for diagnostic purposes; b) the scoring of tissue hybridization-based biomarkers for therapeutic decision-making; and c) the annotation of H&E samples ahead of nucleic acid extraction.

This lecture will discuss in detail our contributions to the application of DP in this areas and, in particular a) the application of QuPath, an open source digital pathology system widely used globally, developed in our laboratory, to the analysis of known biomarkers [5,6]; b) the analysis of markers of adaptive immunity and cancer immunotherapy [7]; and c) the development and utilization of TissueMark®, a product developed to annotate and characterize the H&E of samples ahead of genomic testing [8].

References
1. Soilleux E and Gatter KC. The Antibody Revolution: How ‘Immuno’ Changed Pathology. Chapter 15 in Understanding Disease: A Centenary Celebration of the Pathological Society, 2006, Hall P and Wright NA editors, John Wiley & Sons, Incorporated, ISBN-10 0470032200 & ISBN-13 9780470032206

2. McCourt CM, Boyle D, James J, Salto-Tellez M. Immunohistochemistry in the era of personalised medicine. J Clin Pathol. 2013 Jan;66(1):58-61

3. Morphomolecular pathology: setting the framework for a new generation of pathologists. Jones JL, Oien KA, Lee JL, Salto-Tellez M. Br J Cancer. 2017 Nov 21;117(11):1581-1582. doi: 10.1038/bjc.2017.340.

4. Time for change: a new training programme for morpho-molecular pathologists? Moore DA, Young CA, Morris HT, Oien KA, Lee JL, Jones JL, Salto-Tellez M. J Clin Pathol. 2018 Apr;71(4):285-290.

5. Integrated tumor identification and automated scoring minimizes pathologist involvement and provides new insights to key biomarkers in breast cancer. Bankhead P, Fernández JA, McArt DG, Boyle DP, Li G, Loughrey MB, Irwin

3D mammosphere culture of breast epithelial cell line MCF10A.

Courtesy of Dr. Emer Bourke, NUI Galway

Phospho-Akt expression and localisation

Mediated by VEGF in A549 lung cancer cells. Visualised by high content image analysis.

Courtesy of Dr Martin Barr, Clinical Scientist & Adjunct Assistant Professor, St James’s Hospital & Trinity College Dublin

Metaphase chromosome spread of Jurkat T-lymphoma cells

Courtesy of Rebecca Gorry, PhD Student, Mc Gee Lab, UCD School of Biomolecular & Biomedical Science, Conway Institute, UCD

Apoptosis assessment of SKMES-1 lung cancer cells

Using a multiparameter apoptosis staining kit, showing cell nuclei (blue), actin (green) and mitochondrial activity (orange).

Courtesy of Dr Martin Barr, Clinical Scientist & Adjunct Assistant Professor, St James’s Hospital & Trinity College Dublin

HeLa Cells

Courtesy of Rebecca Gorry, PhD Student, Mc Gee Lab, UCD School of Biomolecular & Biomedical Science, Conway Institute, UCD

IACR & EACR Joint Conference 2020

26 — 28 February 2020 at Galway Bay Hotel, Galway

Mitotic Chronic Myelogenous Leukaemia K562 Cells

Courtesy of Rebecca Gorry, PhD Student, Mc Gee Lab, UCD School of Biomolecular & Biomedical Science, Conway Institute, UCD

Cell to Cell Tweeting

Via nanoparticles (red) in Triple Negative Breast Cancer (TNBC)

Courtesy of Sinéad Lindsay, UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD) Ireland.

Confocal Microscopy Analysis

Of phospho-Akt expression in H460 lung cancer cells in response to hypoxia (0.5% O2).

Courtesy of Dr Martin Barr, Clinical Scientist & Adjunct Assistant Professor, St James’s Hospital & Trinity College Dublin

IACR Membership

We have a number of membership categories available. Find out which membership suits you.

Virtual IACR Cancer Conference

The virtual IACR Annual Meeting takes place 24th - 26th March 2021.

IACR Public Engagement

Would you like to know more about how we involve patients in research, our fundraising, and lay seminars?

Latest News

Education Grant 2020

The Irish Association for Cancer Research supported five Educational Grants in 2020. These were made available to postgraduate PhD researchers who had been affected by the Covid-19
 pandemic. 

FACEBOOK

Irish Association
for Cancer Research  

9A Coolkill, Sandyford
Dublin 18, Ireland
D18 C1W3

info@iacr.ie
+353 (0)295 8859

Irish Association for Cancer Research (IACR) is a registered charity on the Register of Charitable Organisations, Charities Regulator, 3 George's Dock, IFSC, Dublin 1, D01 X5X0, Ireland.

Registered Charity Number (RCN): 20030117.

©Design by LetterEleven